Skip to content
OpenCapital
Get started

Prelude Therapeutics PRLD Q2 2025 earnings

Reported August 14, 2025 · Before market open

Diluted EPS-$0.41Beat by $0.04
EPS estimate-$0.45

Next report

Aug 13, 2026 (in a month)
Revenue estimate$4.8M
EPS estimate-$0.23

Versus estimates

Revenue

Q1 2026$4.6MIn lineQ4 2025$5.6MMiss by $14.9MQ3 2025$6.5MMiss by $14.0MQ4 2024$4.0M

Diluted EPS

Q1 2026-$0.13Beat by $0.14Q4 2025-$0.20Beat by $0.13Q3 2025-$0.26Beat by $0.09
Q2 2025-$0.41Beat by $0.04
Q1 2025-$0.42Beat by $0.05Q4 2024-$0.38Beat by $0.11

Ask the moment Prelude Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Prelude Therapeutics report Q2 2025 earnings?
Prelude Therapeutics (PRLD) reported Q2 2025 earnings on August 14, 2025 before market open.
What were Prelude Therapeutics's Q2 2025 revenue and EPS?
Prelude Therapeutics reported diluted EPS of $-0.41 for Q2 2025.
Did Prelude Therapeutics beat estimates in Q2 2025?
EPS beat the consensus estimate of $-0.45 by $0.04.
How did Prelude Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 10.9% from $-0.46.
Where can I find Prelude Therapeutics's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-108417) directly on SEC EDGAR. The filing index links above go to sec.gov.